Inovio Pharmaceuticals, Inc. Banner Image

Inovio Pharmaceuticals, Inc.

  • Ticker INO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Inovio Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Plymouth Meeting, Pennsylvania
Inovio Pharmaceuticals is developing DNA immune therapies to prevent and treat cancers and infectious diseases. Our SynCon immunotherapies delivered using our proprietary electroporation technology have generated best-in-class immune responses, with therapeutic T-cells exceeding other technologies. In a phase II cervical dysplasia study, our DNA immune therapy induced regression of precancerousMore cervical disease and cleared HPV infection. Roche exclusively licensed Inovio's DNA immunotherapies for prostate cancer and hepatitis B.
4.8 / 5.0 (169)

Inovio Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 169 reviews.

Inovio Pharmaceuticals, Inc.

Most Recent Annual Report

Inovio Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Inovio Pharmaceuticals, Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Inovio Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!